About Courtagen Life Sciences
Courtagen Life Sciences (CLS) provides proteomic and genomic products and services to the Life Sciences industry. The company delivers tools that enable researchers and clinicians to make better decisions regarding drug development and patient care. Avantra Biosciences, a subsidiary of Courtagen Life Sciences, sells instruments, consumables and services to address the need for simple multiplex immunoassays in the research, pre-clinical and clinical diagnostic segments of the Life Sciences industry.
Expert Collections containing Courtagen Life Sciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Courtagen Life Sciences is included in 1 Expert Collection, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Courtagen Life Sciences Patents
Courtagen Life Sciences has filed 8 patents.
Molecular biology, DNA, Biotechnology, Genetics, Polymerase chain reaction
Molecular biology, DNA, Biotechnology, Genetics, Polymerase chain reaction
Latest Courtagen Life Sciences News
Sep 11, 2019
February 10, 2017 -- WOBURN, Mass.--(BUSINESS WIRE)--Medicinal Genomics and Courtagen Life Sciences, today announced an increasingly influential speaker lineup for CannMed 2017. This second annual Personalized Cannabinoid Medicine Conference will be held at The Joseph B. Martin Conference Center at The Harvard School of Medicine April 9-11, 2017. The conference will feature internationally recognized thought leaders, scientists, physicians, and advocates working to advance research into the endocannabinoid system and cannabinoid therapeutics. "We are excited to have the top thought-leaders in medicine, research, and industry on board for our second annual conference to discuss the most important issues impacting the cannabis industry today," said Kevin McKernan, Chief Science Officer, Courtagen. "The conference will showcase the important work of these individuals and cover a range of topics including medical applications for cancer, neurology, and other conditions, mobile applications, and critical topical issues such as opioid dependence and medical cannabis safety related to bacterial and fungal contamination." In addition to Dr. Raphael Mechoulam, cannabis research pioneer and the "Father of Marijuana Research," speakers will include: Michael Dor, MD – Chief Medical Officer of the Israeli Ministry of Foreign Affairs and the Chief Medical Consultant in the Israeli Health Ministry’s Medical Cannabis Unit. Bonni Goldstein, MD – Medical Director of Canna-Centers, a California medical practice devoted to educating patients about the use of cannabis for serious and chronic medical conditions. Elizabeth Anne Thiele, PhD, MD – Director, Pediatric Epilepsy Program at Massachusetts General Hospital. Director, Carol and James Herscot Center for Tuberous Sclerosis Complex. Professor of Neurology, Harvard Medical School. Orrin Devinsky, MD – Professor of Neurology, Neurosurgery, and Psychiatry at the NYU School of Medicine. Devinsky directs the NYU Comprehensive Epilepsy Center and is working on cannabis based clinical studies. Dustin Sulak, DO – founder of Integr8 Health, a medical practice treats over 18,000 patients with medical cannabis, Tested Labs, a cannabis analytic laboratory, and Healer.com, a medical cannabis patient education resource. Jeffrey Hergenrather, MD – President of the Society of Cannabis Clinicians and a cannabis consultation physician who practices in Northern California. Alexandros Makriyannis, PhD – Northeastern University Center for Drug Discovery. Staci Gruber PhD – Director, Cognitive and Clinical Neuroimaging Core and Director, Marijuana Investigations for Neuroscientific Discovery at McLean Hospital. Associate Professor of Psychiatry at Harvard Medical School. Sara Jane Ward, PhD – Assistant Professor, Center for Substance Abuse Research Department of Pharmacology, Lewis Katz School of Medicine at Temple University. Nolan Kane, PhD – Assistant Professor of Ecology and Evolutionary Biology at University of Boulder Colorado. Sean McAllister, PhD – Pharmacologist transforming cancer research to enable more precise therapies and fully personalized cancer care. … and many more! This year’s conference will include an option for health care professionals to earn continuing medical education credits (CMEs) in association with TheAnswerPage.com. Medical practitioners that choose this registration option will also be able to choose a non-profit organization to receive a donation through the Courtagen Gives Back Program. Early-bird discounts are available until February 28th. For additional details or to register for CannMed 2017, visit http://www.cannmedevents.com/ To learn more, visit Facebook, Twitter, and Instagram. Follow on social media with hashtags #CannMed #CannMed2017 Note to editors: Passes are available for accredited media upon request. About Medicinal Genomics Corporation Medicinal Genomics Corporation applies state-of-the-art life science technology to Cannabis plant genetics. Our products help growers, dispensaries, and safety testing laboratories characterize and understand the quality of medicinal cannabis. Medicinal Genomics utilizes a highly sophisticated Next Generation Sequencing laboratory, bioinformatics system, and DNA based technologies to deliver unmatched technical solutions to decipher the genetic code and quality level of medicinal Cannabis. Medicinal Genomics is a wholly owned subsidiary of Courtagen Life Sciences, Inc. For more information, please visit http://www.medicinalgenomics.com/ About Courtagen Life Sciences, Inc. Courtagen Life Sciences, Inc., located in Woburn, MA, is a CLIA/CAP certified molecular information company focused on the diagnosis of a range of neurological disorders. Courtagen operates a highly sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business. Courtagen’s work helps physicians elucidate the linkages between the genotypes and phenotypes of various neurological diseases. For more information, please visit http://www.courtagen.com/ Contacts
Courtagen Life Sciences Frequently Asked Questions (FAQ)
Where is Courtagen Life Sciences's headquarters?
Courtagen Life Sciences's headquarters is located at 8 Cabot Road, Woburn.
What is Courtagen Life Sciences's latest funding round?
Courtagen Life Sciences's latest funding round is Series C.
How much did Courtagen Life Sciences raise?
Courtagen Life Sciences raised a total of $35.12M.
Who are the investors of Courtagen Life Sciences?
Investors of Courtagen Life Sciences include Harbor Light Capital Partners, First Analysis, Adler & Co., Bunker Hill Capital, Massachusetts Life Sciences Center and 3 more.
Who are Courtagen Life Sciences's competitors?
Competitors of Courtagen Life Sciences include Epilog.
Compare Courtagen Life Sciences to Competitors
BrainSpec develops a web-based software platform to make MRS technology accessible to clinicians and researchers alike. The software combines a linear combination model-based post-processing back-end that represents an accurate method of measuring brain metabolites with a highly intuitive and user-friendly front-end web-based user interface. This combination allows for high analytical performance while maintaining ease of use and results in reduced case processing time, leading to higher output and lower costs. The company was founded in 2015 and is based in Boston, Massachusetts.
Alliance operates radiation therapy centers. It provides diagnostic imaging and oncology solutions. It is based in Irvine, California.
Epilog develops solutions to improve the understanding of brain functions. It offers a solution to neurologists for more accurate and efficient computer-aided diagnosis. The company was founded in 2016 and is based in Ghent, Belgium.
Firefly Neuroscience provides clinicians with quantitative and object measurements to aid patients suffering from mental illnesses with brain mapping technology. Its brain network analytics technology provides an objective assessment of cognition. It was formerly known as Elminda. The company was founded in 2006 and is based in TBuffalo, New York. In November 2023, Firefly Neuroscience merged with WaveDancer.